Individuals with mixed atherogenic dyslipidemia, type 2 diabetes mellitus (T2DM), and metabolic syndrome are at high risk of developing cardiovascular disease (CVD) and can often benefit greatly from preventive lifestyle and medical interventions. These conditions typically co-exist in an individual, and the lipid profiles associated with them have several features in common. The worldwide prevalence of T2DM, atherogenic dyslipidemia, and metabolic syndrome is increasing, particularly in southern Asia and the Middle East. Statins can lower low-density lipoprotein-cholesterol and reduce the risk of CVD in these high-risk individuals, but there is a residual risk of CVD associated with additional lipid abnormalities, such as high levels of triglycerides and low levels of high-density lipoprotein cholesterol. These abnormalities are commonly found in patients with T2DM and metabolic syndrome. Additional lipid-modifying therapies that target these abnormalities, such as fibrates and omega-3 polyunsaturated fatty acids, may be able to improve lipid profiles and further reduce the risk of CVD in these patients.
Get full access to this article
View all access options for this article.
References
1.
GinsbergHN, MacCallumPR, HenryN. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr, 2009; 4:113–119.
2.
HorwichTB, FonarowGC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol, 2010; 55:283–293.
3.
BrunzellJD, DavidsonM, FurbergCD, et al.Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care, 2008; 31:811–822.
4.
ReinerŽ, CatapanoAL, De BackerG, et al.ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011; 32:1769–1818.
MooradianAD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab, 2009; 5:150–159.
7.
EckelRH, GrundySM, ZimmetPZ. The metabolic syndrome. Lancet, 2005; 365:1415–1428.
8.
KassiE, PervanidouP, KaltsasG, et al.Metabolic syndrome: Definitions and controversies. BMC Med, 2011; 9:48.
9.
HossainP, KawarB, ElNM. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med, 2007; 356:213–215.
10.
MisraA, KhuranaL. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab, 2008; 93(Suppl 1):S9–S30.
11.
MisraA, ShrivastavaU. Obesity and dyslipidemia in South Asians. Nutrients, 2013; 5:2708–2733.
12.
NolanCJ, DammP, PrentkiM. Type 2 diabetes across generations: From pathophysiology to prevention and management. Lancet, 2011; 378:169–181.
13.
American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care, 2010; 33(Suppl 1):S11–S61.
14.
World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a World Health Organization (WHO) consultation. 2013. Available at http://who.int/diabetes/publications/report-hba1c_2011 pdf
15.
Diabetes UK. HbA1c units converter—DCCT to IFCC. 2013. Available at www.diabetes.co.uk/hba1c-units-converter.html
16.
TabakAG, HerderC, RathmannW, et al.Prediabetes: A high-risk state for diabetes development. Lancet, 2012; 379:2279–2290.
17.
ReavenGM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988; 37:1595–1607.
18.
KahnR, BuseJ, FerranniniE, et al.The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2005; 28:2289–2304.
19.
KahnR. Metabolic syndrome: Is it a syndrome? Does it matter?. Circulation, 2007; 115:1806–1810.
20.
WilsonPW, D'AgostinoRB, LevyD, et al.Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97:1837–1847.
21.
AlbertiKG, EckelRH, GrundySM, et al.Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120:1640–1645.
22.
SibleyC, StoneNJ. Familial hypercholesterolemia: A challenge of diagnosis and therapy. Cleve Clin J Med, 2006; 73:57–64.
BaigentC, KeechA, KearneyPM, et al.Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366:1267–1278.
25.
WierzbickiAS, GrahamCA, YoungIS, et al.Familial combined hyperlipidaemia: Under-defined and under-diagnosed?. Curr Vasc Pharmacol, 2008; 6:13–22.
26.
BrouwersMC, van GreevenbroekMM, StehouwerCD, et al.The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol, 2012; 8:352–362.
27.
ParkH, KimK. Association of alcohol consumption with lipid profile in hypertensive men. Alcohol Alcohol, 2012; 47:282–287.
28.
WakabayashiI. Comparison of the relationships of alcohol intake with atherosclerotic risk factors in men with and without diabetes mellitus. Alcohol Alcohol, 2011; 46:301–307.
29.
LongoM, CrosignaniA, BattezzatiPM, et al.Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut, 2002; 51:265–269.
30.
AppelG. Lipid abnormalities in renal disease. Kidney Int, 1991; 39:169–183.
31.
RadhakrishnanJ, AppelAS, ValeriA, et al.The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis, 1993; 22:135–142.
32.
WheelerDC, BernardDB. Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment. Am J Kidney Dis, 1994; 23:331–346.
33.
O'BrienT, DinneenSF, O'BrienPC, et al.Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc, 1993; 68:860–866.
34.
DursunSM, SzemisA, AndrewsH, et al.The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study. J Psychiatry Neurosci, 1999; 24:453–455.
35.
KasiskeBL, MaJZ, KalilRS, et al.Effects of antihypertensive therapy on serum lipids. Ann Intern Med, 1995; 122:133–141.
36.
ThompsonMA, AbergJA, HoyJF, et al.Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA, 2012; 308:387–402.
37.
Millan Nunez-CortesJ, Pedro-BotetJ, Brea-HernandoA, et al.Use of expert consensus to improve atherogenic dyslipidemia management. Rev Esp Cardiol (Engl Ed), 2014; 67:36–44.
38.
GrundySM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation, 1997; 95:1–4.
39.
TallAR. An overview of reverse cholesterol transport. Eur Heart J, 1998; 19(Suppl A):A31–A35.
40.
GordonDJ, ProbstfieldJL, GarrisonRJ, et al.High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989; 79:8–15.
41.
BarterP, GottoAM, LaRosaJC, et al.HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 2007; 357:1301–1310.
42.
MillerM, StoneNJ, BallantyneC, et al.Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 2011; 123:2292–2333.
43.
HiattWR, SmithRJ. Assessing the clinical benefits of lipid-disorder drugs. N Engl J Med, 2014; 370:396–399.
44.
HarchaouiKE, VisserME, KasteleinJJ, et al.Triglycerides and cardiovascular risk. Curr Cardiol Rev, 2009; 5:216–222.
45.
TalayeroBG, SacksFM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep, 2011; 13:544–552.
46.
LamarcheB, TchernofA, MoorjaniS, et al.Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation, 1997; 95:69–75.
47.
WhitingDR, GuariguataL, WeilC, et al.IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract, 2011; 94:311–321.
48.
WildS, RoglicG, GreenA, et al.Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 2004; 27:1047–1053.
49.
AlmdalT, ScharlingH, JensenJS, et al.The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med, 2004; 164:1422–1426.
50.
BloomgardenZT. Cardiovascular disease and diabetes. Diabetes Care, 2003; 26:230–237.
51.
HaffnerSM, LehtoS, RonnemaaT, et al.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339:229–234.
52.
AlexanderCM, LandsmanPB, TeutschSM, et al.NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 2003; 52:1210–1214.
53.
ZoppiniG, TargherG, TrombettaM, et al.Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. Obesity (Silver Spring), 2009; 17:370–374.
54.
QuertonL, BuysschaertM, HermansMP. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. J Clin Lipidol, 2012; 6:434–442.
55.
KhuntiK, MorrisDH, WestonCL, et al.Joint prevalence of diabetes, impaired glucose regulation, cardiovascular disease risk and chronic kidney disease in South Asians and White Europeans. PLoS One, 2013; 8:e55580.
56.
International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2013. Available at https://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf">
57.
YoonKH, LeeJH, KimJW, et al.Epidemic obesity and type 2 diabetes in Asia. Lancet, 2006; 368:1681–1688.
58.
MisraA, MisraR, WijesuriyaM, et al.The metabolic syndrome in South Asians: Continuing escalation & possible solutions. Indian J Med Res, 2007; 125:345–354.
59.
RamachandranA, MaryS, YamunaA, et al.High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care, 2008; 31:893–898.
60.
SahaN, TayJS, HengCK, et al.DNA polymorphisms of the apolipoprotein B gene are associated with obesity and serum lipids in healthy Indians in Singapore. Clin Genet, 1993; 44:113–120.
61.
PrenticeAM, Rayco-SolonP, MooreSE. Insights from the developing world: Thrifty genotypes and thrifty phenotypes. Proc Nutr Soc, 2005; 64:153–161.
62.
PrenticeAM. The emerging epidemic of obesity in developing countries. Int J Epidemiol, 2006; 35:93–99.
63.
YipAG, MaQ, WilcoxM, et al.Search for genetic factors predisposing to atherogenic dyslipidemia. BMC Genet, 2003; 4(Suppl 1):S100.
64.
GittAK, JungerC, SmolkaW, et al.Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol, 2010; 99:723–733.
65.
JacobsMJ, KleisliT, PioJR, et al.Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract, 2005; 70:263–269.
66.
StamlerJ, VaccaroO, NeatonJD, et al.Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993; 16:434–444.
67.
DrexelH, AczelS, MarteT, et al.Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care, 2005; 28:101–107.
68.
MikhailidisDP, ElisafM, RizzoM, et al.“European panel on low density lipoprotein (LDL) subclasses”: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol, 2011; 9:531–532.
69.
SoneH, MizunoS, FujiiH, et al.Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care, 2005; 28:1463–1471.
70.
MisraA, LuthraK, VikramNK. Dyslipidemia in Asian Indians: Determinants and significance. J Assoc Physicians India, 2004; 52:137–142.
71.
ManjunathCN, RawalJR, IraniPM, et al.Atherogenic dyslipidemia. Indian J Endocrinol Metab, 2013; 17:969–976.
72.
MeenaK, MisraA, VikramN, et al.Cholesterol ester transfer protein and apolipoprotein E gene polymorphisms in hyperlipidemic Asian Indians in North India. Mol Cell Biochem, 2011; 352:189–196.
73.
BhattSP, NigamP, MisraA, et al.Association of the myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in North India. PLoS One, 2012; 7:e40977.
74.
DasM, PalS, GhoshA. Apolipoprotein E gene polymorphism and dyslipidaemia in adult Asian Indians: A population based study from Calcutta, India. Indian J Hum Genet, 2008; 14:87–91.
75.
SharmaM, VikramNK, MisraA, et al.Assessment of 11-beta hydroxysteroid dehydrogenase (11-betaHSD1) 4478T→G and tumor necrosis factor-alpha (TNF-alpha)-308G→A polymorphisms with obesity and insulin resistance in Asian Indians in North India. Mol Biol Rep, 2013;[Epub ahead of print].
76.
GinsbergHN. Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab, 2006; 91:383–392.
77.
GinsbergHN, MacCallumPR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. J Clin Hypertens (Greenwich), 2009; 11:520–527.
78.
McTaggartF, JonesP. Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther, 2008; 22:321–338.
79.
BallantyneCM, OlssonAG, CookTJ, et al.Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation, 2001; 104:3046–3051.
80.
BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation, 2000; 102:21–27.
81.
CostaJ, BorgesM, DavidC, et al.Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials. BMJ, 2006; 332:1115–1124.
82.
DeedwaniaP, BarterP, CarmenaR, et al.Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet, 2006; 368:919–928.
83.
DownsJR, ClearfieldM, WeisS, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998; 279:1615–1622.
84.
FrickMH, EloO, HaapaK, et al.Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med, 1987; 317:1237–1245.
85.
GelukCA, AsselbergsFW, HillegeHL, et al.Impact of statins in microalbuminuric subjects with the metabolic syndrome: A substudy of the PREVEND Intervention Trial. Eur Heart J, 2005; 26:1314–1320.
86.
GinsbergHN, ElamMB, LovatoLC, et al.Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362:1563–1574.
87.
KeechA, SimesRJ, BarterP, et al.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 2005; 366:1849–1861 [Erratum in: Lancet 2006;368:1415].
88.
LeeM, SaverJL, TowfighiA, et al.Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis, 2011; 217:492–498.
89.
ManninenV, TenkanenL, KoskinenP, et al.Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation, 1992; 85:37–45.
90.
RubinsHB, RobinsSJ, CollinsD, et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 1999; 341:410–418.
91.
SeverPS, DahlöfB, PoulterNR, et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet, 2003; 361:1149–1158.
92.
ShepherdJ, CobbeSM, FordI, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333:1301–1307.
93.
CollinsR, ArmitageJ, ParishS, et al.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet, 2003; 361:2005–2016.
94.
JafriH, Alsheikh-AliAA, KarasRH. Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med, 2010; 153:800–808.
95.
LimS, ParkYM, SakumaI, et al.How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol, 2013; 166:8–14.
96.
SirimarcoG, LabreucheJ, BruckertE, et al.Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke, 2014; 45:1429–1436.
97.
LiaoJK. Safety and efficacy of statins in Asians. Am J Cardiol, 2007; 99:410–414.
98.
NakamuraH, ArakawaK, ItakuraH, et al.Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet, 2006; 368:1155–1163.
99.
ChapmanN, ChangCL, CaulfieldM, et al.Ethnic variations in lipid-lowering in response to a statin (EVIREST): A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn Dis, 2011; 21:150–157.
100.
BaigentC, BlackwellL, EmbersonJ, et al.Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376:1670–1681.
101.
EmbersonJR, KearneyPM, BlackwellL, et al.Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One, 2012; 7:e29849.
102.
ZafrirB, JainM. Lipid-lowering therapies, glucose control and incident diabetes: Evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther, 2014; 28:361–377.
103.
SattarN, PreissD, MurrayHM, et al.Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375:735–742.
104.
YoonJS, LeeHW. Diabetogenic effect of statins: a double-edged sword?. Diabetes Metab J, 2013; 37:415–422.
105.
GrundySM, CleemanJI, DanielsSR, et al.Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005; 112:2735–2752.
106.
American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care, 2014; 37(Suppl 1):S14–S80.
107.
FruchartJC, SacksFM, HermansMP, et al.The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res, 2008; 5:319–335.
108.
TenenbaumA, FismanEZ, MotroM, et al.Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins. Cardiovasc Diabetol, 2006; 5:20.
109.
JunM, FooteC, LvJ, et al.Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. Lancet, 2010; 375:1875–1884.
110.
StaelsB, DallongevilleJ, AuwerxJ, et al.Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998; 98:2088–2093.
111.
FrickMH, SyvanneM, NieminenMS, et al.Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation, 1997; 96:2137–2143.
112.
TenenbaumA, FismanEZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: Spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol, 2012; 11:125.
113.
ScottR, O'BrienR, FulcherG, et al.Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 2009; 32:493–498.
114.
TenenbaumA, MotroM, FismanEZ, et al.Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med, 2005; 165:1154–1160.
115.
AthyrosVG, TziomalosK, KaragiannisA, et al.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: The case for residual risk reduction after statin treatment. Open Cardiovasc Med J, 2011; 5:24–34.
116.
CorsiniA, BellostaS, DavidsonMH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol, 2005; 96:44K–49K.
117.
LaszloA, KalabayL, NemcsikJ. Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: Contradictions between the two main therapeutic pathways. BMC Res Notes, 2013; 6:52.
118.
Alsheikh-AliAA, KuvinJT, KarasRH. Risk of adverse events with fibrates. Am J Cardiol, 2004; 94:935–938.
119.
GanjiSH, KamannaVS, KashyapML. Niacin and cholesterol: Role in cardiovascular disease (review). J Nutr Biochem, 2003; 14:298–305.
120.
LeeJM, RobsonMD, YuLM, et al.Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol, 2009; 54:1787–1794.
121.
VillinesTC, StanekEJ, DevinePJ, et al.The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol, 2010; 55:2721–2726.
122.
Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA, 1975; 231:360–381.
123.
BodenWE, ProbstfieldJL, AndersonT, et al.Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365:2255–2267.
124.
BrownBG, ZhaoXQ, ChaitA, et al.Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med, 2001; 345:1583–1592.
125.
BrownG, AlbersJJ, FisherLD, et al.Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med, 1990; 323:1289–1298.
126.
BruckertE, LabreucheJ, AmarencoP. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis, 2010; 210:353–361.
127.
CannerPL, BergeKG, WengerNK, et al.Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol, 1986; 8:1245–1255.
128.
ElamMB, HunninghakeDB, DavisKB, et al.Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA, 2000; 284:1263–1270.
129.
GrundySM, VegaGL, McGovernME, et al.Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med, 2002; 162:1568–1576.
130.
HPS2-THRIVE Collaborative Group, HaynesR, HopewellJC, et al.Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med, 2014; 371:203–212.
131.
GoldbergRB, JacobsonTA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc, 2008; 83:470–478.
132.
GuytonJR, FazioS, AdewaleAJ, et al.Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care, 2012; 35:857–860.
133.
SazonovV, MaccubbinD, SiskCM, et al.Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract, 2013; 67:297–302.
134.
European Medicines Agency (EMA). European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn. 2013. Available at www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/01/news_detail_001694.jsp&mid=WC0b01ac058004d5c1
135.
AndersonTJ, BodenWE, Desvigne-NickensP, et al.Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med, 2014; 371:288–290.
136.
Kris-EthertonPM, HarrisWS, AppelLJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 2002; 106:2747–2757.
137.
BurrML, FehilyAM, GilbertJF, et al.Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet, 1989; 2:757–761.
138.
GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet, 1999; 354:447–455.
139.
YokoyamaM, OrigasaH, MatsuzakiM, et al.Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet, 2007; 369:1090–1098.
140.
BallantyneCM, BaysHE, KasteleinJJ, et al.Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol, 2012; 110:984–992.
141.
BaysHE, BallantyneCM, KasteleinJJ, et al.Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol, 2011; 108:682–690.
142.
KromhoutD, GiltayEJ, GeleijnseJM, et al.n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med, 2010; 363:2015–2026.
143.
BoschJ, GersteinHC, DagenaisGR, et al.n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med, 2012; 367:309–318.
144.
RoncaglioniMC, TombesiM, AvanziniF, et al.n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med, 2013; 368:1800–1808.
145.
HooperL, ThompsonRL, HarrisonRA, et al.Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review. BMJ, 2006; 332:752–760.
146.
RauchB, SchieleR, SchneiderS, et al.OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation, 2010; 122:2152–2159.
147.
AthyrosVG, MikhailidisDP. Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 fatty acid ethyl esters. Open Cardiovasc Med J, 2012; 6:122–125.
148.
DavidsonMH, SteinEA, BaysHE, et al.Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. Clin Ther, 2007; 29:1354–1367.
149.
MakiKC, OrloffDG, NichollsSJ, et al.A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther, 2013; 35:1400–1411.
150.
SinghRB, NiazMA, SharmaJP, et al.Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival–4. Cardiovasc Drugs Ther, 1997; 11:485–491.
151.
SaitoY, YokoyamaM, OrigasaH, et al.Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis, 2008; 200:135–140.
152.
PooleCD, HalcoxJP, Jenkins-JonesS, et al.Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: A retrospective, matched-cohort study. Clin Ther, 2013; 35:40–51.
153.
IsoH, KobayashiM, IshiharaJ, et al.Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation, 2006; 113:195–202.
154.
BarterPJ, CaulfieldM, ErikssonM, et al.Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357:2109–2122.
155.
SchwartzGG, OlssonAG, AbtM, et al.Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 367:2089–2099.
156.
RashidS, SnidermanA, MeloneM, et al.Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. Eur J Prev Cardiol, 2014;2047487314528461. First Published March21, 2014.
157.
BaigentC, LandrayMJ, ReithC, et al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011; 377:2181–2192.
158.
CannonCP, GiuglianoRP, BlazingMA, et al.Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J, 2008; 156:826–832.
159.
KasteleinJJ, AkdimF, StroesES, et al.Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med, 2008; 358:1431–1443.
160.
GeL, WangJ, QiW, et al.The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab, 2008; 7:508–519.
161.
BlazingMA, GiuglianoRP, CannonCP, et al.Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. Am Heart J, 2014; 168:205–212.
162.
SteinEA, MellisS, YancopoulosGD, et al.Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med, 2012; 366:1108–1118.
163.
SteinEA, GipeD, BergeronJ, et al.Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet, 2012; 380:29–36.
164.
SullivanD, OlssonAG, ScottR, et al.Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA, 2012; 308:1–10.
165.
RaalF, ScottR, SomaratneR, et al.Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/Kexin Type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation, 2012; 126:2408–2417.
166.
American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care, 2013; 36Suppl 1:S11–S66.
167.
JellingerPS, SmithDA, MehtaAE, et al.American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract, 2012; 18(Suppl 1):1–78.
168.
Guasch-FerreM, BulloM, Martinez-GonzalezMA, et al.Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial. BMC Med, 2013; 11:164.
169.
StoneNJ, RobinsonJ, LichtensteinAH, et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013; 63:2889–2934.
170.
American Association of Clinical Endocrinologists. Member alert regarding new guidelines. 2013. Available at https://www.aace.com/sites/all/files/Member_Alert_Re_Guidelines_112113.pdf
171.
RayKK, KasteleinJJ, BoekholdtSM, et al.The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J, 2014; 35:960–968.
